Periocular Adverse Reactions to Omidenepag Isopropyl.

PURPOSE: To investigate the periocular adverse reactions to omidenepag isopropyl (OMDI). DESIGN: Nonrandomized comparative clinical study. METHODS: We enrolled 100 patients (100 eyes) with primary open-angle glaucoma or ocular hypertension who received initial treatment with OMDI or tafluprost in only 1 eye for ≥6 months. Photographs of the eyelids were taken on the day of the participants' visit after ≥6 months of prescription. Subsequently, 3 ophthalmologists individually determined the occurrence of eyelid pigmentation, eyelash growth, and deepening of the upper eyelid sulcus (DUES). Additionally, a questionnaire on the subjective symptoms was administered. Multivariate analysis of baseline data was performed to investigate the factors involved in adverse reactions. RESULTS: The mean duration of drug administration was 10.2 ± 3.8 and 10.8 ± 4.1 months in the OMDI and tafluprost groups, respectively. The frequencies of eyelid pigmentation, eyelash growth, and DUES were 0.0%, 0.0%, and 2.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 4.0%, 32.0%, and 12.0%. The only significant difference was that the OMDI group showed fewer patients with eyelash growth than in the tafluprost group (P < .0001). In the questionnaire, the subjective symptoms of eyelid pigmentation, eyelash growth, and DUES were 8.0%, 2.0%, and 4.0%, respectively, in the OMDI group, whereas the corresponding values in the tafluprost group were 12.0%, 40.0%, and 4.0%, respectively. Multivariate analysis revealed a correlation between the type of drug administered and these adverse reactions (R = 0.38, P = .005). CONCLUSIONS: The frequencies of periocular adverse reactions to OMDI, ranging from 0% to 2.0%, were lower than those to tafluprost.

Switching from concomitant therapy to tafluprost/timolol fixed combination.

PURPOSE: To evaluate the efficacy and safety of tafluprost/timolol fixed combination (TTFC). STUDY DESIGN: A prospective clinical study. METHODS: Twenty-eight patients (28 eyes) with primary open-angle glaucoma, who had used tafluprost and timolol gel for at least 3 months with good adherence, were enrolled. Concomitant administration of tafluprost and timolol was switched to TTFC without a washout period. The intraocular pressure (IOP), blood pressure, pulse rate, and ocular signs were compared between before switching (baseline), and 4 and 8 weeks after switching. A questionnaire survey was also performed 4 weeks after switching to investigate ocular comfort and patient preferences. RESULTS: The IOP showed no significant change after switching to TTFC (14.8 ± 2.8, 14.6 ± 3.4, and 14.8 ± 3.7 mmHg at baseline, Week 4, and Week 8, respectively). The pulse rate and systolic blood pressure showed no changes, but diastolic blood pressure was significantly lower at Week 8. At baseline, fluorescein staining revealed corneal abnormalities in 3 patients, which resolved by Week 8 in 1 patient. Hyperemia was noted in 2 patients at baseline, and this also resolved by Week 8 in 1 patient. Three patients discontinued study treatment for the following reasons (1 patient each): blurred vision; ocular irritation, eyelid erythema, and asthenopia; and loss to follow-up from Week 8. The questionnaire survey revealed no significant differences between the 2 treatments, although more patients preferred TTFC. CONCLUSION: Among 28 patients enrolled, only 2 patients discontinued the study treatment due to adverse reactions. In patients whose adherence was considered relatively good to concomitant therapy, switching to TTFC achieved similar IOP control with good safety and a high level of patient acceptance.

Contact-based stiffness sensing of human eye.

Goldmann applanation tonometry is commonly used for measuring intraocular pressure (IOP) to diagnose glaucoma. However, the measured IOP by conventional applanation tonometry is valid only under the assumption that all subjects have the same structural eye stiffness. This paper challenges in vivo measurement of eye stiffness with a noninvasive approach and investigates individual differences of eye stiffness. Eye stiffness is defined by the applied force and displacement of the cornea. The displacement is detected based on captured images by a high resolution camera. The experimental results show that the measured stiffness nicely matches the analytical result that is derived from a simple spherical deformation model with an internal pressure. However, some subjects have different eye stiffness even with the same IOP. IOP with abnormal stiffness may be over/underestimated by conventional applanation tonometry. The proposed eye stiffness measurement can help detect the misestimated eye and it contributes to the early detection of glaucoma.

Simultaneous measurement of eye stiffness and contact area for living human eyes.

Goldmann applanation tonometry is commonly used for measuring IOP (IntraOcular Pressure) to diagnose glaucoma. However, the measured IOP by the applanation tonometry is valid only under the assumption that all the subjects have the same structural eye stiffness. Abnormal eye stiffness makes abnormal corneal deformation and thus the current applanation tonometer misestimates the IOP. This study challenges to measure the eye stiffness in vivo with a non-invasive approach for detecting the abnormal deformation. The deformation of the cornea and the contact area between the probe and the cornea are simultaneously captured by cameras during the experiment. Experimental results show that some subjects have different relationship among the force, the displacement and the contact area even with same IOP. The proposed eye stiffness measurement can help detecting the abnormal deformation and the eyes with misestimated IOP.